Prevention of breast tumour development in vivo by downregulation of the P185neureceptor

Makoto Katsumata, Tadao Okudaira, Arabinda Samanta, Douglas P. Clark, Jeffrey A. Drebin, Paul Jolicoeur, Mark I. Greene

Research output: Contribution to journalArticlepeer-review

Abstract

Certain strains of transgenic mice that express the rat neu oncogene (neuT) in mammary epitheiial ceiis develop breast tumours at an average of 44 weeks of age. In this study, intraperitoneal injection of a monoclonal anti-receptor antibody specific for the rat neuJ oncogene product dramatically affected tumour development in these transgenic mice in a dose-dependent manner. A significant proportion (50%) of mice, when injected with anti-receptor antibodies, did not develop tumours even after 90 weeks of age. The phosphotyrosine levels of the membrane fraction of breast tissues in the anti-receptor antibody-treated mice were almost completely abolished when a higher dose of antibodies was used. This study demonstrates, for the first time, that immunologic manipulation of an oncogene product can effectively prevent the development of tumours in a rodent transgenic model.

Original languageEnglish (US)
Pages (from-to)644-648
Number of pages5
JournalNature medicine
Volume1
Issue number7
DOIs
StatePublished - Jul 1995

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Prevention of breast tumour development in vivo by downregulation of the P185<sup>neu</sup>receptor'. Together they form a unique fingerprint.

Cite this